• Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 4  |  Issue : 1  |  Page : 1-8

I-Kappa-B kinase-epsilon activates nuclear factor-kappa B and STAT5B and supports glioblastoma growth but amlexanox shows little therapeutic potential in these tumors


1 Department of Human Genetics, GIGA Research Center, University of Liege, Domaine Du Sarttilman, B35, 4000 Liege, Belgium
2 Department of Neurology and Neurosurgery, Rudolf Magnus Brain Center, University Medical Center of Utrecht, 100 Leuvenlaan, 3584 CX Utrecht, The Netherlands
3 Department of Human Genetics, GIGA Research Center, University of Liege, Domaine Du Sarttilman, B35, 4000 Liege, Belgium; Department of Neurology and Neurosurgery, Rudolf Magnus Brain Center, University Medical Center of Utrecht, 100 Leuvenlaan, 3584 CX Utrecht, The Netherlands

Correspondence Address:
Prof. Pierre Alain Robe
Department of Neurology and Neurosurgery, Rudolf Magnus Brain Center, University Medical Center of Utrecht, 100 Leuvenlaan, 3584 CX Utrecht, The Netherlands

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ctm.ctm_3_18

Rights and Permissions

Aim: This study aims to analyze the role of I-kappa-B kinase (IKK)-epsilon in glioblastoma (GBM). Methods: A series of in vitro, in vivo, microarray, and immunohistochemical assessments were performed to evaluate the biological effects of IKK-epsilon on cell signaling, radiation sensitivity, and patient survival in GBM condition. Results: IKK-epsilon was strongly expressed in 75% of 195 primary GBM samples but did not correlate with patient survival. No correlation was established between the copy number, messenger RNA (mRNA) expression, and protein expression in 38 fresh tumor samples, nor between IKK-epsilon mRNA expression and survival in 543 GBM of the TCGA repository. In vitro, IKK-epsilon contributed to the growth and migration of glioma cells, independent of their EGFRVIII status. IKK-epsilon activated nuclear factor (NF)-κB and STAT5B in vitro, confirming the observed correlation surgical GBM samples. IKK-epsilon silencing did not alter the sensitivity of GBM cells to ionizing radiation. Amlexanox, inhibitor of IKK-epsilon and TBK1, poorly (IC50 > 100 μM) decreased cell growth and increased NF-κB activity in GBM cells, in vitro, notably due to TBK1 inhibition. In vivo, oral amlexanox failed to inhibit the growth of intracerebral U87 GBM xenografts in nude mice. Conclusion: The results confirm a moderate pro-oncogenic role of IKK-epsilon in GBM, but question the potential of amlexanox as a therapeutic drug.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed897    
    Printed45    
    Emailed0    
    PDF Downloaded155    
    Comments [Add]    

Recommend this journal